DART Therapeutics appoints executive team

Friday, September 14, 2012 01:51 PM

DART Therapeutics, a Cambridge, Mass.-based new-model biotechnology firm focused on developing therapies for Duchenne Muscular Dystrophy (DMD), has appointed an executive team. Members include co-founder and executive chairman Eugene W. Williams with the new title of CEO, Ernest D. Bush, PhD, as chief scientific officer., Dr. Elliot Goldstein as chief medical officer, and Cabot Brown as chief financial officer.

Williams bring more than 25 years of experience as a senior manager at major biotech firms, including Genzyme, an innovator and pioneer in pediatric rare diseases, as well as experience serving as founder/executive chairman of numerous entrepreneurial life sciences ventures. He brings experience and accomplishment in pediatric rare diseases, global development, business development, portfolio management and entrepreneurship.

Bush has more than 30 years of experience in biomedical R&D for major pharmaceutical companies, including Hoffman La-Roche, where he was responsible for the preclinical safety department at Nutley, N.J., as well as the non-clinical assessment of in-licensing candidates.

Goldstein brings more than 25 years of executive-level pharmaceutical and biotechnology expertise to DART with senior management roles at Sandoz, Novartis, SB (now GSK) and Maxygen.

Brown has co-founded several advisory and investment banking firms, including Carabiner, Seven Hills Group and Brown, McMillan & Co. Brown has spent more than 25 years working as an advisor to and investor in numerous companies across many segments of the healthcare industry.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

April 14

Proposal calls for back-to-back trials to measure efficacy and effectiveness prior to FDA approval

Study: Minority populations under-represented in cancer trials, but have higher rates of incidence

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

April

Make way for mobile health in clinical trials
Despite patient retention, data quality benefits, regulatory hurdles persist

Global clinical trial laboratories decentralize
Regional labs reducing complexity, delivering cost and time savings

Already a subscriber?
Log in to your digital subscription.

Purchase the April issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

March

Strategic alliances hit bumps in the road
Mixed relationship performance driving new approaches

Tapping community hospitals for clinical trial volunteers
New study finds high potential but infrastructure, resources are lacking

Already a subscriber?
Log in to your digital subscription.

Purchase the March issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs